Wave Life Sciences Ltd - Asset Resilience Ratio
Wave Life Sciences Ltd (WVE) has an Asset Resilience Ratio of 13.80% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2017)
This chart shows how Wave Life Sciences Ltd's Asset Resilience Ratio has changed over time. Check WVE strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Wave Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Wave Life Sciences Ltd (WVE) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $25.04 Million | 13.8% |
| Total Liquid Assets | $25.04 Million | 13.80% |
Asset Resilience Insights
- Moderate Liquidity: Wave Life Sciences Ltd has 13.80% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Wave Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Wave Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Wave Life Sciences Ltd (2015–2017)
The table below shows the annual Asset Resilience Ratio data for Wave Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $181.84 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $164.81 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $165.42 Million | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more